BioSpace News Archive

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”) today announced that it has signed a data sharing agreement with the study leadership of a randomized, placebo-controlled trial of 156 patients hospitalized for Acute Suicidality and Depression in 7 French Government Hospitals.

OKYO Pharma Limited announced the closing of its previously announced Company best efforts registered direct offering of 2,666,670 ordinary shares at an offering price of $1.50 per ordinary share conducted without an underwriter or placement agent to individuals and institutions.

908 Devices Inc., a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announced it will participate in the upcoming Gilmartin Group Emerging Growth Company Showcase.

Catalent, Inc. announced that, on September 14, 2023, it received a notice from the New York Stock Exchange that the Company is not in compliance with the NYSE’s continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual, because the Company did not timely file its Annual Report on Form 10-K for the fiscal year ended June 30, 2023 with the Securities and Exchange Commission.

Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced dosing of the first patients with small cell lung cancer (SCLC) in an ongoing Phase 1/2 trial of HPN328, a DLL3 targeting TriTAC®, in combination with atezolizumab (Tecentriq®).

Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, appointed pharmaceutical executive Alexandre Gibim as the company’s Chief Operations Officer.

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper) today announced that it will participate at the Cantor Fitzgerald 2023 Global Healthcare Conference, to be held from September 26-28, 2023 in New York City.

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointment of Ms. Minnie Kuo as Chief Development Officer.

Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced financial results for the second quarter ended June 30, 2023, along with recent business updates.

Ascendis Pharma A/S (Nasdaq: ASND) today announced the launch in Germany of SKYTROFA® (lonapegsomatropin), its growth hormone approved in the European Union for the once-weekly treatment of children and adolescents ages 3 to 18 years with growth failure due to insufficient endogenous growth hormone secretion (growth hormone deficiency, or GHD).